A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Ceralasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms PATRIOT
- 07 Oct 2019 Planned End Date changed from 1 Sep 2020 to 1 Dec 2020.
- 07 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 30 Sep 2020.
- 16 Sep 2019 According to an AstraZeneca media release, results from this study will be presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, 27 September to 1 October 2019.